Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	747M 645M 595M 557M 1.04B 71.03B 1.06B 7.02B 2.74B 34.57B 2.8B 2.74B 120B	P/E Ratio 2025 *	-	P/E Ratio 2026 *	-
Enterprise Value	424M 367M 338M 316M 593M 40.35B 602M 3.99B 1.56B 19.64B 1.59B 1.56B 67.99B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	99.99%	Yield 2025 *	-	Yield 2026 *	-

01-23	Astria Therapeutics, Inc. Announces Board Resignations	CI
01-23	BioCryst Pharmaceuticals, Inc. completed the acquisition of Astria Therapeutics, Inc. from group of shareholders.	CI
01-23	Biocryst Pharmaceuticals, Inc. Announces Board and Executive Changes	CI
01-23	BioCryst Pharmaceuticals Closes Acquisition of Astria Therapeutics	MT
01-22	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from S&P Global BMI Index	CI
01-22	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from S&P TMI Index	CI
01-22	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from NASDAQ Composite Index	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell Small Cap Comp Value Benchmark	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell Microcap Value Benchmark Index	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell 3000E Value Benchmark	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell 3000 Value Benchmark	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell 2500 Value Benchmark	CI
01-21	Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell 2000 Value Benchmark	CI

12-30	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
11-12	Cantor Fitzgerald Downgrades Astria Therapeutics to Neutral From Overweight	MT
25-10-16	HC Wainwright Downgrades Astria Therapeutics to Neutral From Buy	MT
25-04-29	Cantor Fitzgerald Initiates Astria Therapeutics at Overweight $47 Price Target	MT
25-03-12	Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating	MT

01-21	Astria Stockholders Vote to Approve Acquisition by BioCryst	BU
11-12	Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update	BU
11-06	Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart	BU
11-03	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	AQ
25-10-31	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	BU

25-10-14	USA-Les valeurs à suivre à Wall Street (actualisé)
25-10-02	Astria Therapeutics recrute actuellement des patients atteints d’angio-œdème héréditaire dans l’Union européenne pour l’essai de phase III ALPHA-ORBIT
25-10-02	Astria Therapeutics sta arruolando pazienti affetti da angioedema ereditario (HAE) nell’Unione Europea per il trial di fase 3 ALPHA-ORBIT
25-10-02	Astria Therapeutics inicia la inscripción de pacientes con AEH de la Unión Europea para el ensayo ALPHA-ORBIT de fase III
25-10-02	Astria Therapeutics schrijft nu HAE-patiënten in de Europese Unie in voor de ALPHA-ORBIT Fase 3-studie

Catabasis Pharmaceuticals Inc Stock Nasdaq

Stocks

US14875P1075

Biotechnology & Medical Research

Valuation: Catabasis Pharmaceuticals Inc

Latest news : Catabasis Pharmaceuticals Inc

Last Transcript: Catabasis Pharmaceuticals Inc

Analysts' recommendations: Catabasis Pharmaceuticals Inc

Press Releases: Catabasis Pharmaceuticals Inc

News in other languages: Catabasis Pharmaceuticals Inc

Quotes and Performance

Managers and Directors: Catabasis Pharmaceuticals Inc

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Babar Ghias PSD	President	47	2026-01-22
Alane Barnes SEC	Corporate Secretary	60	2026-01-22
Elizabeth Higgins IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Babar Ghias BRD	Director/Board Member	47	2026-01-22
Alane Barnes BRD	Director/Board Member	60	2026-01-22

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CATABASIS PHARMACEUTICALS INC	+1.92%	+17.83%	-	-	718M
ARGENX SE	+1.03%	+2.30%	+54.92%	+111.78%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+47.26%	+47.26%	44.54B
BIONTECH SE	+1.12%	+2.79%	-13.71%	-17.53%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	+1.00%	+401.79%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+12.00%	-29.52%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.10%	-40.04%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.17%	+178.31%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+14.25%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+92.88%	+215.31%	11.15B
Average	+1.81%	+2.09%	+27.21%	+108.42%	23.75B
Weighted average by Cap.	+1.72%	+2.37%	+31.92%	+100.38%

	2025 *	2026 *
Net sales	-	-
Net income	-123M -106M -97.71M -91.46M -171M -11.67B -174M -1.15B -450M -5.68B -461M -451M -19.67B	-
Net Debt	-	-